Oragenics (OGEN) Net Income (2010 - 2026)
Oragenics' (OGEN) quarterly Net Income came in at -$2.2 million in Q1 2026, up 0.71% YoY from -$2.2 million in Q1 2025, and up 8.99% on a QoQ basis from -$2.4 million in Q4 2025.
Oragenics (OGEN) Net Income (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Net Income data on file, last reported at -$2.2 million in Q1 2026.
- Quarterly Net Income rose 0.71% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.0 million (up 3.95% YoY) and the FY2025 annual result came in at -$9.9 million, up 6.93% from the prior year.
- Net Income grew to -$2.2 million in Q1 2026, from -$2.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.0 million in Q3 2023 to a low of -$12.7 million in Q4 2023.
- A 5-year average of -$3.4 million and a median of -$2.5 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income sank 469.66% — and 2024, when it surged 73.52%.
- Tracing OGEN's Net Income over 5 years: stood at -$2.2 million in 2022, then slumped by 469.66% to -$12.7 million in 2023, then surged by 73.52% to -$3.4 million in 2024, then increased by 28.36% to -$2.4 million in 2025, then grew by 8.99% to -$2.2 million in 2026.
- The last three Net Income figures came in at -$2.2 million (Q1 2026), -$2.4 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 81.49 Mn |
| 10 | Oragenics | 2.35 Mn | 2.35 Mn | - | -2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.53 Mn |
| Mar 31, 2026 | -2.20 Mn |
| Dec 31, 2025 | -2.42 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.22 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.45 Mn |
| Dec 31, 2023 | -12.75 Mn |
| Sep 30, 2023 | -2.01 Mn |
| Jun 30, 2023 | -3.05 Mn |
| Mar 31, 2023 | -2.84 Mn |
| Dec 31, 2022 | -2.24 Mn |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -3.59 Mn |
| Mar 31, 2022 | -4.59 Mn |
| Dec 31, 2021 | -2.29 Mn |
| Sep 30, 2021 | -4.38 Mn |